Biomerica Inc. (NASDAQ:BMRA) saw an upside of 38.00% to close Friday at $6.21 after adding $1.71 on the day. The 5-day average trading volume is 19,097,041 shares of the company’s common stock. It has gained $6.60 in the past week and touched a new high 2 times within the past 5 days. An average of 4,818,230 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,995,228.
BMRA’s 1-month performance is 35.00% or $1.61 on its low of $4.05 reached on 09/14/21. The company’s shares have touched a 52-week low of $3.30 and high of $8.15, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, BMRA has achieved 24.70% or $1.23 and has reached a new high 9 times. However, the current price is down -23.80%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Biomerica Inc. (BMRA) has a trailing price-to-earnings (P/E) ratio of 26.75 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects.BMRA stock has a beta of -0.67. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.82 while the price-to-book (PB) in the most recent quarter is 8.28.
Biomerica Inc.’s quick ratio for the period ended May 30 was 4.60, with the current ratio over the same period at 7.10 meaning that BMRA stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending May 30 was 0.00, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 6.90%The trailing 12-month EBITDA margin is -85.38% while for the period ending May 30; Biomerica Inc.’s operating margin was -90.60%. The firm’s gross profit as reported stood at $0.5 million against revenue of $7.2 million.
For the quarterly period ending May 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected BMRA to announce -$0.11 per share in earnings in its latest quarter, but it posted -$0.12, representing a -9.10% surprise. EBITDA for the quarter stood at more than -$1.4 million. BMRA stock balance sheet for the quarter ending May 30 shows that total liabilities totaled 2.59 million, with total debt at $1.62 million. Shareholders hold equity totaling $12.51 million
Let’s look briefly at Biomerica Inc. (BMRA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 76.30% to suggest the stock is trending Overbought, with historical volatility in this time period at 169.67%.
The stock’s 5-day moving average is $5.03, reflecting a +21.05% or $1.08 change from its current price. BMRA is currently trading +35.89% above its 20-day SMA, +82.11% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +58.82% and +8.38% respectively.
Stochastic %K and %D was 54.80% and 52.35% and the average true range (ATR) pointed at 0.53. The RSI (14) points at 72.75%, while the 14-day stochastic is at 84.71% with the period’s ATR at 0.44. The stock’s 9-day MACD Oscillator is pointing at 0.23 and 0.45 on the 14-day charts.
In the most recent analyst report for Biomerica Inc. (NASDAQ: BMRA), Colliers Securities launched coverage with a Buy rating. Analysts offering their rating for BMRA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BMRA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is BMRA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $13.00 and a high of $13.00, with their median price target at $13.00. Looking at these predictions, the average price target given by analysts is for Biomerica Inc. (BMRA) stock is $13.00.